|
|
|
| Advances in the treatment of neuroparalytic keratitis |
| SUN Yaru ZHAO Haixia |
| PRK Center, the Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia Autonomous Region, Hohhot 010050, China |
|
|
|
Abstract Neuroparalytic keratitis is also called as neurotrophic keratitis. When trigeminal nerve suffers from trauma, surgery, inflammation or tumor destruction, the sensitivity of cornea losing eneurosis will be decreased and the dystrophia will be occurred, the defense capability for the external harmful factors will be weakened, thus, the corneal epithelium will turn dry and be susceptible to mechanical damage. What's worse, it will probably result in corneal ulcer, fusion and perforation. The therapeutic aim of neuroparalytic keratitis is to promote corneal healing and prevent the progress of corneal damage. The treating methods include physical therapy, drug therapy, operative treatment, and so on. In recent years, the novel therapeutic strategies, such as local application of nerve growth factor, pay attention to improve the eneurosis of cornea and support corneal growth and healing.
|
|
|
|
|
|
[1] 葛坚，王宁利.眼科学[M].3版.北京：人民卫生出版社，2015：199.
[2] Sacchetti M，Lambiase A. Neurotrophic factors and corneal nerve regeneration [J]. Neural Regen Res，2017，12（8）：1220-1224.
[3] Gasset AR，Kaufman HE. Therapeutic uses of hydrophilic contact lenses [J]. Am J Ophthalmol，1970，69（2）：252-259.
[4] Shafran T，Gleason W，Osbom LK，et al. Application of seno?鄄filcon acontact lenses for therapeutic bandage lens indications [J]. Eye Contact Lens，2013，39（5）：315-323.
[5] Kanpolat A，Ucakhan OO. Therapeutic use of Focus Night & Day contact lenses [J]. Cornea，2003，22（8）：726-734.
[6] Bonini S，Rama P，Olzi D，et al. Neurotrophic keratitis [J]. J Fr Ophtalmol，2004，27（2）：200-201.
[7] Kloek CE，Jeng-Miller KW，Jacobs DS，et al. Prosthetic replacement of the ocular surface ecosystem treatment of ocular surface disease after skull base tumor resection [J]. World Neurosurg，2017，10（28）：1-5.
[8] Sanchezavila RM，Merayolloves J，Riestra AC，et al. Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors（PRGF-Endoret）eye-drops [J]. Int Ophthalmol，2017，6（15）：1-12.
[9] Feroze KB，Bhimji SS. Keratitis，Neurotrophic [M]. Treasure Island（FL）：Stat Pearls Publishing，2017：7.
[10] Arvola RP，Robciuc A，Holopainen JM，et al. Matrix regeneration therapy：a case series of corneal neurotrophic ulcers [J]. Cornea，2016，35（4）：451-455.
[11] Muñoz-Hernández AM，Santos-Bueso E，Cui?觡a-Sardi?觡a R，et al. New therapies for neurotrophic keratitis [J]. Arch Soc Esp Oftalmol，2016，91（3）：105-107.
[12] Jeng BH，Dupps WJ Jr. Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects [J]. Cornea，2009，28（10）：1104-1108.
[13] Cavanagh HD，Colley AM. The molecular basis of neurotrophic keratitis [J]. Acta Ophthalmol Suppl，1989，67（192）：115-134.
[14] Mantelli F，Nardella C，Tiberi E，et al. Congenital corneal anesthesia and neurotrophic keratitis：diagnosis and management [J]. Biomed Res Int，2015，9（16）：315-323.
[15] Yanai R，Nishida T，Chikama T，et al. Potential new modes of treatment of neurotrophic Keratopathy [J]. Cornea，2015， 34（3）：303-307.
[16] Semeraro F，Forbice E，Romano V，et al. Neurotrophic keratitis [J]. Ophthalmologica，2014，231（4）：191-197.
[17] Ortuño-Prados VJ，Alio JL. Treatment of a neurotrophic corneal ulcer with solid platelet-rich plasma and Tutopatch? [J]. Arch Soc Esp Oftalmol，2011，86（4）：121-123.
[18] 李凤鸣.中华眼科学[M].北京：人民卫生出版社，2005：888.
[19] 明春平，史伟云，李曼.部分永久性睑缘缝合术治疗持续性角膜上皮缺损27例[J].眼科新进展，2008，28（6）：449-452.
[20] Uhlig CE，Frings C，Rohloff N，et al. Long-term efficacy of glycerine-processed amniotic membrane transplantation in patients with corneal ulcer [J]. Acta Ophthalmol，2015，93（6）：481-487.
[21] Kasparova EA，Sobkova OI，Kasparova EA，et al. Surgical treatment of purulent corneal ulcers in eyes with neurotrophic keratitis and paralytic lagophthalmos [J]. Vestn Oftalmol，2017，133（5）：32-37.
[22] 曾波，周雄，周和政，等.羊膜移植联合泪道栓对神经麻痹性角膜炎泪膜及愈合的影响[J].华南国防医学杂志，2014，28（6）：564-568.
[23] 张勐，冯永格，张红霞，等.羊膜移植治疗神经麻痹性角膜炎12例[J].白求恩军医学院学报，2011，9（2）：106-107.
[24] Sacchetti M，Lambiase A. Diagnosis and management of neurotrophic keratitis [J]. Clin Ophthalmol，2014，19（8）：571-579.
[25] Kasaee A，Musavi MR，Tabatabaie SZ，et al. Evaluation of eicacy and safety of botulinum toxin type A injection in patients requiring temporary tarsorrhaphy to improve corneal epithelial defects [J]. Int J Ophthalmol，2010，3（3）：237-240.
[26] Ellis MF，Daniell M. An evaluation of the safety and efficacy of botulinum toxin type A (BOTOX) when used to produce a protective ptosis [J]. Clin Exp Ophthalmol，2001， 29（6）：394-399.
[27] Aloe L，Rocco ML，Balzamino BO，et al. Nerve growth factor：a focus on neuroscience and therapy [J]. Curr Neuropharmacol，2015，13（3）：294-303.
[28] Sacchetti M，Lambiase A. Neurotrophic factors and corneal nerve regeneration [J]. Neural Regen Res，2017，12（8）：1220-1224.
[29] Di G，Qi X，Zhao X，et al. Corneal epithelium-derived neurotrophic factors promote nerve regeneration [J]. Invest Ophthalmol Vis Sci，2017，58（11）：4695-4702.
[30] Matsuyama A，Takatori S，Sone Y，et al. Effect of nerve growth factor on innervation of perivascular nerves in neovasculatures of mouse cornea [J]. Biol Pharm Bull，2017， 40（4）：396-401.
[31] He J，Cortina MS，Kakazu A，et al. The PEDF neuroprotective domain plus DHA induces corneal nerve regeneration after experimental surgery [J]. Invest Ophthalmol Vis Sci，2015，56（6）：3505-3513.
[32] Micera A，Lambiase A，Puxeddu I，et al. Nerve growth factor effect on human primary fibroblastickeratocytes：possible mechanism during corneal healing [J]. Exp Eye Res，2006，83（4）：747-757.
[33] Sornelli F，Lambiase A，Mantelli F，et al. NGF and NGF receptor expression of cultured immortalized human corneal endothelial cells [J]. Mol Vis，2010，29（16）：1439-1447.
[34] 杨丕坚，李舒敏，吕以培，等.鼠神经生长因子治疗糖尿病痛性神经病变疗效观察[J].中华实用诊断与治疗杂志，2013，27（6）：589-591.
[35] 李雪丽，勾晓梅，隋源，等.鼠神经生长因子（mNGF）治疗神经麻痹性角膜炎[C]//广州：世界中医学会联合会眼科年会中华中医药学会中医中西医结合眼科学术大会论文集，2011：108-109. |
|
|
|
